Overview

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

This research study is a Feasibility clinical trial. In this trial, researchers are trying to figure out whether a medication can be chosen based on rapid testing done on tumor tissue. Information from a feasibility or pilot trial will hopefully help researchers plan larger trials in the future to determine the effect of this therapy.

Phase:

N/A

Details

Lead Sponsor:

Seattle Children's Hospital

Collaborator:

Cures Within Reach

Treatments:

Dacarbazine
Dasatinib
Erlotinib Hydrochloride
Etoposide
Etoposide phosphate
Everolimus
Niacinamide
Sirolimus
Sorafenib
Temozolomide